Y-BOX BINDING PROTEIN YB-1 IDENTIFIES HIGH-RISK PRIMARY BREAST CANCER PATIENTS BENEFITING FROM RAPIDLY CYCLED TANDEM HIGH-DOSE ADJUVANT CHEMOTHERAPY

被引：0
|
作者：
Gluz, O. [1 ]
Mengele, K.
Schmitt, M. [2 ]
Kates, R.
Diallo-Danebrock, R. [3 ]
Royer, H. [4 ]
Eckstein, N. [4 ]
Mohrmann, S. [3 ]
Nitz, U. [1 ]
Harbeck, N. [5 ]
机构：
[1] Breast Clin Niederrhein, W German Study Grp, Monchengladbach, Germany
[2] Tech Univ Munich, Clin Gynaecol & Obstet, Munich, Germany
[3] Univ Duesseldorf, Dusseldorf, Germany
[4] CAESAR, Bonn, Germany
[5] Tech Univ Munich, Klinikum Rechts Isar, Frauenklin, D-8000 Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：55 / 55
页数：1
相关论文
共 50 条
  • [41] Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer
    S. Hohaus
    S. Martin
    A. Schneeweiß
    M. T. Voso
    R. F. Schlenk
    D. Wallwiener
    G. Bastert
    R. Haas
    Cancer Chemotherapy and Pharmacology, 1999, 44 : S13 - S17
  • [42] Should breast reconstruction be delayed in high-risk breast cancer patients (pts) receiving High-Dose Chemotherapy (HDC)?
    Petit, J
    Youssef, O
    Rjetjens, M
    D'Ambrosio, M
    Luini, A
    Massaron, S
    Vanazzi, A
    Martinelli, G
    BONE MARROW TRANSPLANTATION, 2001, 27 : S119 - S119
  • [43] Sequential high-dose chemotherapy with peripheral blood stem cell (PBSC) support as adjuvant therapy for patients with high-risk breast cancer.
    Hohaus, S
    Wallwiener, D
    Schneeweiss, A
    Egerer, G
    Martin, S
    Abdallah, A
    Goldschmidt, H
    Fersis, N
    Bastert, G
    Haas, R
    BONE MARROW TRANSPLANTATION, 1998, 22 : S93 - S94
  • [44] Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
    V Drageset
    JM Nesland
    B Erikstein
    E Skovlund
    H Sommer
    G Anker
    E Wist
    S Lundgren
    J Bergh
    G Kvalheim
    Breast Cancer Research, 7
  • [45] Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
    Drageset, V
    Nesland, JM
    Erikstein, B
    Skovlund, E
    Sommer, H
    Anker, G
    Wist, E
    Lundgren, S
    Bergh, J
    Kvalheim, G
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S56 - S57
  • [46] HIGH-RISK EPENDYMOMAS ARE DISTINGUISHABLE BY ELEVATED EXPRESSION OF THE EPIDERMAL GROWTH FACTOR AND THE Y-BOX BINDING PROTEIN-1
    Hukin, J.
    Law, J. H.
    Yip, S.
    Maguire, J.
    Yamashita, T.
    Fryer, C.
    Singhal, A.
    Ailon, T.
    Hendson, G.
    Hawkins, C.
    Dunn, S. E.
    NEURO-ONCOLOGY, 2010, 12 (06) : II26 - II26
  • [47] Tandem high-dose chemotherapy (HDC) versus dose-dense conventional chemotherapy for patients with high-risk breast cancer (HRBC) - interim results from a multicenter phase III trial
    Frick, M
    Mohrmann, S
    Eimermacher, H
    Ko, J
    Ziske, C
    Koch, O
    Kleinschmidt, R
    Fischer, J
    Fiebich, C
    Bender, HG
    Nitz, U
    BONE MARROW TRANSPLANTATION, 1999, 23 : S39 - S39
  • [48] HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT AS CONSOLIDATION AFTER STANDARD-DOSE ADJUVANT THERAPY FOR HIGH-RISK PRIMARY BREAST-CANCER
    PETERS, WP
    ROSS, M
    VREDENBURGH, JJ
    MEISENBERG, B
    MARKS, LB
    WINER, E
    KURTZBERG, J
    BAST, RC
    JONES, R
    SHPALL, E
    WU, K
    ROSNER, G
    GILBERT, C
    MATHIAS, B
    CONIGLIO, D
    PETROS, W
    HENDERSON, IC
    NORTON, L
    WEISS, RB
    BUDMAN, D
    HURD, D
    JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (06) : 1132 - 1143
  • [49] High-dose chemotherapy with stem cell support in high-risk primary breast cancer. Effect on overall survival
    Palshof, T
    BONE MARROW TRANSPLANTATION, 2004, 33 : S39 - S39
  • [50] Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy
    van Dam, FSAM
    Schagen, SB
    Muller, MJ
    Boogerd, W
    von der Wall, E
    Fortuyn, MED
    Rodenhuis, S
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (03) : 210 - 218
12345